Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Urologic / Genitourinary Cancers

22 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Bladder

    VICCURO1322

    03/28/2014

    Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

    Health Services Research

    Prostate

    VICCURO1638

    06/29/2015

    Patient-Centered Treatment Decision-Making in Advanced Prostate Cancer

    Other

    Prostate

    URO70807-M

    05/10/2012

    Men's Eating and Living Study: A Randomized trial of diet to alter disease progression in prostste cancer patients on active surveillance

    Supportive Care

    Bladder

    VICCURO99007

    03/24/2014

    A Pilot Study of Perioperative Oral Nutrition Supplementation to Improve Nutritional Status and Clinical Outcomes in Patients Undergoing Radical Cystectomy

    Treatment

    Bladder
    Urologic

    VICCURO15119

    06/14/2016

    Phase II Trial of Palbociclib (PD-0332991) in Patients with Metastatic Urothelial Cancer (UC) after Failure of First-Line Chemotherapy

    Treatment

    Kidney (Renal Cell)

    VICCURO15127

    06/01/2016

    A Randomized Phase 2 Trial of AXITINIB and TRC105 versus AXITINIB Alone (Including a Lead-In Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma

    Treatment

    Bladder
    Colon
    Gastric/Gastroesophageal
    Kidney (Renal Cell)
    Rectal
    Urologic

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    Prostate

    ECOGUROR0924

    03/10/2016

    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

    Treatment

    Bladder

    ECOGUROGU001

    02/29/2016

    Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer

    Treatment

    Bladder

    VICCURO15139

    02/01/2016

    Observation Versus Immediate Surgery for Low Risk Bladder Cancer

    Treatment

    Bladder

    ECOGUROS1314

    01/18/2016

    A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

    Treatment

    Bladder
    Breast
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Gynecologic
    Head/Neck
    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell
    Pancreatic
    Rectal
    Urologic
    Uterine

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    Bladder

    VICCURO1559

    09/02/2015

    An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with Non-Muscle Invasive Bladder Carcinoma Who have Failed BCG Therapy and Refused Cystectomy

    Treatment

    Bladder
    Urologic

    ECOGUROEA8141

    08/27/2015

    A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

    Treatment

    Prostate

    VICCURO1540

    07/08/2015

    A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men with High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy. MDV3100-13

    Treatment

    Prostate

    VICCURO1473

    01/09/2015

    A Randomized Phase II Study of Androgen Deprivation Therapy with or without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer.

    Treatment

    Prostate

    CTSUALLIANCEURO031201-M

    11/21/2014

    URO A031201: Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

    Treatment

    Prostate

    VICCURO1450

    08/13/2014

    PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

    Treatment

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Treatment

    Prostate

    CTSUUROS1216-M

    01/16/2014

    A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

    Treatment

    Prostate

    CTSUUROC90203-M

    11/05/2007

    A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer


    Print this page for your doctor